Cis-Diamminebichloroplatinum as a Therapeutic Agent in Metastatic Transitional Cell Carcinoma

Abstract

Cis-platinum as single agent therapy was investigated in 8 patients with stage D transitional cell carcinoma of the bladder. Dramatic responses were obtained in some patients and the quality of life was improved for as long as 8 months but no cures were obtained. Also noted was an occasional marked loss of renal function as measured by creatinine clearance despite a carefully managed protocol to avert this known side effect of cis-platinum (nephrotoxicity). No auditory problems were noted in these 8 patients.

Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma

“…The median survival for untreated invasive bladder cancer is 6 to 9 months for those with distant metastatic disease and 18 months for those with locally advanced disease and/or involved regional lymph nodes. The most active conventional single agents include cisplatin (Yagoda et al, 1976;Merrin, 1978;Rossof et al, 1979;Herr, 1980;Peters and MR, 1980;Oliver et al, 1981), methotrexate (Natale et al, 1981;Oliver et al, 1984), vinblastine (Blumenreich et al, 1982) and doxorubicin (Yagoda et al, 1977). Pooled data from Phase II studies indicate a response rate of 30% for cisplatin (95% CI 25-35%) and 29% for methotrexate (95% CI 23-35%) (Yagoda, 1987).…”

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

“…To define better the role of cartherapy in Phase II and III trials have not been as boplatin-based therapy in the treatment of this disencouraging. [5][6][7][8][9][10] However, it still remains the mainstay ease, we conducted a randomized trial to compare Mof current combination chemotherapy for the treat-VAC (selected as the representative standard cisplatin ment of advanced bladder carcinoma in clinical praccombination in bladder carcinoma treatment) and Mtice. It is a main component of several regimens, such CAVI regimens in the treatment of patients with surgias cisplatin, cyclophosphamide, and doxorubicin cally incurable advanced bladder carcinoma who had (CISCA), 11 cisplatin, methotrexate, and vinblastine adequate renal function.…”